ResoTher Pharma receives a €2.5 million grant from European Innovation Council (EIC) to support a Phase 2a clinical study of their Lead Candidate RTP-026 for Myocardial Infarction

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ResoTher-Pharma-EIC

More Like This

PR Newswire associated0

Heart Failure start-up, Acorai, secures €2.3m grant funding from the European Commission

PR Newswire associated0

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

PR Newswire associated0

INHEART RAISES $11M TO ACCELERATE DEVELOPMENT & DEPLOYMENT OF NOVEL THERAPEUTIC, PREDICTIVE, AND SCREENING CARDIAC SOLUTIONS

International Research Collaboration Aims to Personalise Prevention and Treatment of Cardiovascular Diseases

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

Business Wire logo

Reflow Medical Enrolls First Patients in Pilot Study of Coronary Sirolimus-Eluting Retrievable Scaffold System (Spur Elute)

PR Newswire associated0

Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings

PR Newswire associated0

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million